The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of what it was once worth years ago.
The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...
(NASDAQ:BLUE) lost ~37% in the premarket on Friday after the gene therapy developer announced its plans to become a privately held biotech as part of an M&A agreement with private equity firms Carlyle ...
According to Benzinga Pro, Carlyle Group's peer group average for short interest as a percentage of float is 3.15%, which means the company has more short interest than most of its peers. Did you know ...
Sedgwick, a provider of claims management, loss adjusting and technology-enabled business solutions, has agreed to acquire Thoma Bravo -based Bottomline’s legal spend management division. No financial ...
The star-studded cast for the brand new Netflix series is as follows: The trailer dropped on 5th February, and sees Jodie ...
Record revenues from management fees and a brighter outlook for M&A in the year ahead helped private equity's Big Four close 2024 on a high note.
Bank of America Securities analyst Craig Siegenthaler maintained a Sell rating on Carlyle Group (CG – Research Report) yesterday and set a ...
The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...
For the arts institution, which receives only a small portion of its budget from federal funding, the perennial challenge is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results